An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer-A Systematic Review of Randomized Phase II and III Clinical Trials.

导出 LinkOut

翻译打印收藏纠错

作者： Ioana-Miruna,Stanciu ^[1] ; Andreea Ioana,Parosanu ^[1] ; Cornelia,Nitipir ^[1]

作者单位： Department of Oncology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.;Department of Medical Oncology, Elias University Emergency Hospital, 011461 Bucharest, Romania. ^[1]

关键词 CDK4/6 inhibitor toxicities abemaciclib breast cancer palbociclib ribociclib safety profile

主题词人类(Humans);女(雌)性(Female);乳腺肿瘤(Breast Neoplasms);细胞周期蛋白依赖激酶4(Cyclin-Dependent Kinase 4);临床试验, Ⅱ期(主题)(Clinical Trials, Phase II as Topic)

DOI 10.3390/biom13091422

PMID 37759823

发布时间 2024-09-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Biomolecules

2023年13卷9期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer-A Systematic Review of Randomized Phase II and III Clinical Trials.

Biomolecules

相似文献

Biomolecules

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer-A Systematic Review of Randomized Phase II and III Clinical Trials.

Biomolecules

相似文献

Biomolecules

相关期刊

检索历史清除